



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Reducing Blood Loss during Open Myomectomy with Intra-Myometrial Injection of Vasopressin versus Octreotide Acetate: A Double Blinded Randomized Controlled Trial

Thesis

*Submitted for Partial Fulfilment of Master Degree
in Obstetrics & Gynaecology*

By

Mohamed Abd El Rahim Sadek Kenawy
M.B.B.Ch., Faculty of Medicine – Cairo University (2014)

Under Supervision of

Dr. Alaa El-Din Hamed El-Feky

*Professor of Obstetrics & Gynecology
Faculty of Medicine, Ain Shams University*

Dr. Mohamed Abdellatif Abdelhaleem

*Assistant Professor of Obstetrics & Gynecology
Faculty of Medicine, Ain Shams University*

Faculty of Medicine, Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Dr. Alaa El-Din Hamed El-Feky**, Professor of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Dr. Mohamed Abdellatif Abdelhaleem**, Assistant Professor of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, for his sincere efforts, fruitful encouragement.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Mohamed Abd El Rahim Sadek Kenawy

List of Contents

Title	Page No.
List of Abbreviations.....	5
List of Tables.....	6
List of Figures	7
Introduction	- 1 -
Aim of the Work	11
Review of Literature	
▪ Uterine Leiomyomas	12
▪ Uterine Leiomyomas Management	39
▪ Techniques to Reduce Blood Loss during Abdominal or Laparoscopic Myomectomy	66
▪ Vasopressin.....	77
▪ Octreotide Acetate	83
Patients and Methods.....	89
Results.....	94
Discussion	113
Summary	120
Conclusion	125
Recommendations	126
References	127
Arabic Summary	

List of Abbreviations

Abb.	Full term
ADH	<i>Antidiuretic hormone</i>
AUB	<i>Abnormal uterine bleeding</i>
AVP	<i>Arginine vasopressin</i>
BMI	<i>Body mass index</i>
ECM	<i>Major extracellular matrix</i>
FDA	<i>Food and Drug Administration</i>
FH	<i>Fumarate hydratase gene</i>
FIGO	<i>Federation of Gynecology and Obstetrics</i>
GnRH	<i>Gonadotropin releasing hormone</i>
HIFU	<i>High-intensity focused ultrasound</i>
HLRCC	<i>Hereditary leiomyomatosis and renal cell carcinoma syndrome</i>
HMB	<i>Heavy menstrual bleeding</i>
ITT	<i>Intention to treat</i>
IUS	<i>Intrauterine system</i>
LARCs	<i>Long-acting reversible contraceptives</i>
LVP	<i>Lysine vasopressin</i>
MED12	<i>Mediator complex subunit 12</i>
MRI	<i>Magnetic resonance imaging</i>
NSAIDs	<i>Nonsteroidal anti-inflammatory drugs</i>
OA	<i>Octreotide Acetate</i>
PDS	<i>Polydioxanone</i>
RF	<i>Radio frequency</i>
SARCs	<i>Short acting hormonal contraceptives</i>
SPSS	<i>Statistical Package for Social Sciences</i>
UAE	<i>Uterine artery embolization</i>
UFE	<i>Uterine fibroid embolization</i>
WDHA	<i>Watery diarrhea / hypokalemic / achlorhydria</i>

List of Tables

Table No.	Title	Page No.
Table 1:	Age, Parity, BMI and complaint of all patients included in the study.	97
Table 2:	Comparison between studied groups as regard age, Parity, BMI and Complaint.	99
Table 3:	Comparison between studied group as regard pre-operative Hb, pre-operative HCT, post-operative Hb and post-operative HCT.	100
Table 4:	Comparison between studied group as regard Operative time, blood loss, blood transfusion and hospital stay.	103
Table 5:	Comparison between studied group as regard complications.	106
Table 6:	Comparison between studied group as regard pre-operative SBP, pre-operative DBP, pre-operative HR, post-operative SBP, post-operative DBP, post-operative HR and size of myoma.	107
Table 7:	Comparison between studied groups as regard mean difference in Hb, HCT, SBP, DBP and HR.	109
Table 8:	Correlation in OA group between blood loss and age, parity, BMI, HB-pre, HB-post, HCT-pre, HCT-post, operative time, vital signs, size of myoma. Correlation in Vasopressin group between blood loss and age, parity, BMI, HB-pre, HB-post, HCT-pre, HCT-post, operative time, vital signs, size of myoma.	111

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Fibroid locations in the uterus and hysterectomy specimen showing multiple leiomyomas	13
Figure 2:	Submucosal leiomyoma position: European society of hysteroscopy classification	14
Figure 3:	Pedunculated fibroid	15
Figure 4:	Uterine leiomyoma and cystic degeneration of uterine leiomyoma	27
Figure 5:	Fibroid in 53 year old woman who presented with postmenopausal bleeding.....	31
Figure 6:	Palm-coe-in classification system for abnormal uterine bleeding in non-gravid reproductive age women.....	33
Figure 7:	Abdominal myomectomy	57
Figure 8:	Closure of myomectomy.....	58
Figure 9:	Uterine blood supply	67
Figure 10:	Abdominal myomectomy: use of a uterine artery tourniquet and ovarian artery clamps	73
Figure 11:	Somatostatin and octreotide	84
Figure I:	Flow chart of the study.....	94
Figure II:	Parity of the patients.....	98
Figure III:	Compliance of the patients.....	98
Figure IV:	Comparison between studied groups as regard post-operative HCT.....	101
Figure V:	Comparison between studied groups as regard post-operative Hb.....	102
Figure VI:	Comparison between studied groups as regard Operative time.	104
Figure VII:	Comparison between studied groups as regard Blood loss.	105

List of Figures *cont...*

Fig. No.	Title	Page No.
Figure VIII:	Comparison between studied groups as regard mean difference in Hb.	110
Figure IX:	Comparison between studied groups as regard mean difference in HCT.	110
Figure X:	Correlation between blood loss and operative time.	112

INTRODUCTION

There are various pharmacological and non-pharmacological methods that have been tested to control haemorrhage during myomectomy. At present, there is moderate-quality evidence that misoprostol or vasopressin may reduce bleeding during myomectomy, and low-quality evidence that bupivacaine plus epinephrine, tranexamic acid, gelatin-thrombin matrix, ascorbic acid, dinoprostone, loop ligation, fibrin sealant patches, peri-cervical tourniquet, or tourniquet tied around both cervix and infundibulopelvic ligaments may reduce bleeding during myomectomy. There is no evidence that oxytocin, morcellation or temporary clipping of the uterine artery reduce blood loss (*Kongnyuy et al., 2014*).

Vasopressin, a synthetic analogue of the posterior pituitary hormone antidiuretic hormone, is a pharmacological agent that is often injected into the uterus to reduce blood loss during surgery (*Cohen et al., 2017*).

Injection of vasopressin is analogous to a medical tourniquet, with vasoconstrictive effects at the V1 receptors within the uterus. Administration of vasopressin also stimulates uterine contraction by myometrial V1a receptors (*Chudnoff et al., 2012*).

Compared with placebo, vasopressin has been shown to decrease blood loss, blood transfusion and operative time during myomectomy (*Zhang et al., 2015*).

On the other hand, and because it is a potent systemic vasoconstrictor, vasopressin may cause hypertension and bradycardia. It has a plasma half-life of 10-20 minutes. Care should be taken to infiltrate a dilute solution with hemodynamic monitoring. To avoid unwanted surges in blood pressure. The anti-diuretic activity of vasopressin can last for two to eight hours. This can be easily reversed with an intravenous diuretic like Frusemide (*Sinha et al., 2011*).

In developing countries, vasopressin is not routinely used during conventional myomectomy due to non-availability and high cost, and therefore other less effective methods are used to reduce bleeding during open or laparoscopic myomectomy (*Sinha et al., 2011*).

Octreotide Acetate (OA) (Sandostatine), is an octapeptide that mimics natural somatostatin pharmacologically. It is commonly used as an adjuvant agent in the management of variceal bleeding (*Koul et al., 2012*).

It was also concluded that OA has a local arterial vasoconstrictive effect in patients with cirrhosis that is independent of systemic hormonal modulation of glucagon, this vasomotor action seems to be independent of Nitric Oxide (*Alempijević et al., 2015*).

AIM OF THE WORK

The aim of the study was to assess the efficacy of local injection of OA in reducing blood loss during conventional abdominal myomectomy, and to compare it with local injection of vasopressin.

Primary outcome: Intra-operative blood loss was estimated by adding the volume in the suction container after completion of each procedure with the estimated blood loss from weighing of the soaked laparotomy mop packs which was placed dry in the abdomen after opening the parietal peritoneum.

Secondary outcome: Operative time and complications was registered. Postoperative parameters included haemoglobin values, need for blood transfusion and other complications was also tabulated.

Study hypothesis: In women undergoing open myomectomy, local injection of OA may be effective in reducing blood loss during conventional abdominal myomectomy.

Study question: In women undergoing open myomectomy, is local injection of OA more effective than local injection of vasopressin in reducing blood loss during conventional abdominal myomectomy?

Chapter 1

UTERINE LEIOMYOMAS

Uterine leiomyomas (also referred to as fibroids or myomas) are the most common pelvic tumor in women (*Baird et al., 2011*). They are noncancerous monoclonal tumors arising from the smooth muscle cells and fibroblasts of the myometrium. They arise in reproductive-age women and, when symptomatic, typically present with symptoms of abnormal uterine bleeding and/or pelvic pain/pressure. Uterine fibroids may also have reproductive effects (e.g., infertility, adverse pregnancy outcomes) (*Wu et al., 2017*).

Terminology and location:

Uterine fibroids are described according to their location in the uterus although many fibroids have more than one location designation.